KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Inventory Average (2016 - 2025)

Historic Inventory Average for Pacific Biosciences Of California (PACB) over the last 15 years, with Q3 2025 value amounting to $53.5 million.

  • Pacific Biosciences Of California's Inventory Average fell 2035.2% to $53.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.5 million, marking a year-over-year decrease of 2035.2%. This contributed to the annual value of $57.7 million for FY2024, which is 782.2% up from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Inventory Average of $53.5 million as of Q3 2025, which was down 2035.2% from $53.9 million recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year Inventory Average high stood at $68.0 million for Q2 2024, and its period low was $15.2 million during Q1 2021.
  • For the 5-year period, Pacific Biosciences Of California's Inventory Average averaged around $47.0 million, with its median value being $53.9 million (2025).
  • In the last 5 years, Pacific Biosciences Of California's Inventory Average skyrocketed by 11956.37% in 2022 and then plummeted by 2066.47% in 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Inventory Average (Quarter) stood at $21.4 million in 2021, then soared by 118.95% to $46.9 million in 2022, then soared by 33.08% to $62.5 million in 2023, then dropped by 0.35% to $62.2 million in 2024, then fell by 14.06% to $53.5 million in 2025.
  • Its Inventory Average was $53.5 million in Q3 2025, compared to $53.9 million in Q2 2025 and $56.4 million in Q1 2025.